Skip to main content
Clinical Trials/NL-OMON39121
NL-OMON39121
Completed
Not Applicable

Assessment of Comorbidities in COPD in European Symptomatic Subjects from primary care. - ACCESS

GlaxoSmithKline0 sites480 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COPD
Sponsor
GlaxoSmithKline
Enrollment
480
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Males/females \>\= 40 years of age.
  • 2\. COPD (all GOLD\-stages) diagnosed \>\= 12 months ago.
  • 3\. FEV1/FVC (tiffeneau\-index) after use of bronchodilator \< 0\.70\.
  • 4\. Smoking history of \>\= 10 packyears
  • 5\. Singed informed consent form.

Exclusion Criteria

  • 1\.In the opinion of the investigator, there is a current primary diagnosis of asthma (patients with a primary diagnosis of COPD but who also have asthma may be included)
  • 2\.A diagnosis of fibrosis or asbestosis
  • 3\.Diagnosis of cancer \- includes current and within the last 5 years (patients in remission for \>\= 5 years may be included). Patients diagnosed with cancer during the study will be withdrawn
  • 4\.Diagnosis of clinically significant bronchiectasis
  • 5\.Subjects who are concurrently participating in any clinical study or who have received any investigational drugs within 4 weeks of Visit 1, or who will start any during the study period.
  • 6\.Unable to or unwilling to conform with the study requirements including completion of the health status questionnaires
  • 7\.Females who are pregnant or lactating.

Outcomes

Primary Outcomes

Not specified

Similar Trials